Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses

J Immunol. 2014 Dec 15;193(12):5933-50. doi: 10.4049/jimmunol.1401702. Epub 2014 Nov 12.

Abstract

Class-switch DNA recombination (CSR) and somatic hypermutation (SHM), which require activation-induced cytidine deaminase (AID), and plasma cell differentiation, which requires B lymphocyte-induced maturation protein-1 (Blimp-1), are critical for the generation of class-switched and hypermutated (mature) Ab and autoantibody responses. We show that histone deacetylase inhibitors valproic acid and butyrate dampened AICDA/Aicda (AID) and PRDM1/Prdm1 (Blimp-1) mRNAs by upregulating miR-155, miR-181b, and miR-361 to silence AICDA/Aicda, and miR-23b, miR-30a, and miR-125b to silence PRDM1/Prdm1, in human and mouse B cells. This led to downregulation of AID, Blimp-1, and X-box binding protein 1, thereby inhibiting CSR, SHM, and plasma cell differentiation without altering B cell viability or proliferation. The selectivity of histone deacetylase inhibitor-mediated silencing of AICDA/Aicda and PRDM1/Prdm1 was emphasized by unchanged expression of HoxC4 and Irf4 (important inducers/modulators of AICDA/Aicda), Rev1 and Ung (central elements for CSR/SHM), and Bcl6, Bach2, or Pax5 (repressors of PRDM1/Prdm1 expression), as well as unchanged expression of miR-19a/b, miR-20a, and miR-25, which are not known to regulate AICDA/Aicda or PRDM1/Prdm1. Through these B cell-intrinsic epigenetic mechanisms, valproic acid blunted class-switched and hypermutated T-dependent and T-independent Ab responses in C57BL/6 mice. In addition, it decreased class-switched and hypermutated autoantibodies, ameliorated disease, and extended survival in lupus MRL/Fas(lpr/lpr) mice. Our findings outline epigenetic mechanisms that modulate expression of an enzyme (AID) and transcription factors (Blimp-1 and X-box binding protein 1) that are critical to the B cell differentiation processes that underpin Ab and autoantibody responses. They also provide therapeutic proof-of-principle in autoantibody-mediated autoimmunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / immunology
  • Antibodies / metabolism
  • Antibody Formation*
  • Autoantibodies / biosynthesis
  • Autoantibodies / immunology
  • B-Lymphocytes / cytology
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / physiology*
  • Cell Differentiation / drug effects
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Cytidine Deaminase / genetics*
  • DNA Methylation / drug effects
  • DNA-Binding Proteins / genetics
  • Dose-Response Relationship, Drug
  • Epigenesis, Genetic*
  • Female
  • Gene Expression Regulation / drug effects
  • Gene Knockout Techniques
  • Gene Silencing*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Immunoglobulin Class Switching / drug effects
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Mice
  • Mice, Inbred MRL lpr
  • MicroRNAs / genetics*
  • Plasma Cells / cytology
  • Plasma Cells / drug effects
  • Plasma Cells / immunology
  • Plasma Cells / metabolism
  • Positive Regulatory Domain I-Binding Factor 1
  • Regulatory Factor X Transcription Factors
  • Repressor Proteins / genetics*
  • Somatic Hypermutation, Immunoglobulin / drug effects
  • Transcription Factors / genetics

Substances

  • Antibodies
  • Autoantibodies
  • DNA-Binding Proteins
  • Histone Deacetylase Inhibitors
  • MicroRNAs
  • Regulatory Factor X Transcription Factors
  • Repressor Proteins
  • Transcription Factors
  • PRDM1 protein, human
  • Positive Regulatory Domain I-Binding Factor 1
  • AICDA (activation-induced cytidine deaminase)
  • Cytidine Deaminase